2m 2m 2m 2m 2m 2m 2m
CRISPR THERAP N (CRSP)
NASDAQ
$54.07-$0.29 (-0.53%)
Price as of Jun 23, 2026 7:07 PM EDT- $5.4BMarket Cap
- 19.34%1-Year Change
- BiotechnologyIndustry
CRISPR THERAP N (CRSP)
$54.07-$0.29 (-0.53%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 -100.00% | 37.3M -89.95% | 371.2M +30,885.48% | 1.2M -99.87% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 -100.00% | 37.3M -89.95% | 371.2M +30,885.48% | 1.2M -99.87% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -284.8M -11.18% | -320.7M -17.21% | -387.3M -16.10% | -461.6M +5.25% | |
Depreciation and Amortization Expense | 19.5M +1.14% | 19.3M -2.91% | 19.8M -17.93% | 24.2M +34.64% | |
Total Operating Expenses | 668.1M +32.59% | 503.9M -15.14% | 593.7M -11.95% | 674.4M +24.55% | |
Operating Profit | -664.6M +42.44% | -466.6M +109.66% | -222.5M -66.94% | -673.2M -280.22% | |
Interest Income | N/A N/A | 104.3M N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 -100.00% | 104.3M N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 86.6M -16.65% | 103.9M +44.68% | 71.8M +216.91% | 22.7M +277.49% | |
Income before Taxes | -578.0M +59.37% | -362.7M +140.62% | -150.7M -76.83% | -650.5M -271.40% | |
Income Taxes | 3.6M +1.31% | 3.6M +24.20% | 2.9M +988.62% | -325,000 -117.38% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -581.6M +58.80% | -366.3M +138.43% | -153.6M -76.37% | -650.2M -272.16% | |
Net Income from Continuing Operations Applicable to Common | -578.0M +59.37% | -362.7M +140.62% | -150.7M -76.83% | -650.5M -271.40% | |
Basic EPS and Net Income | -6.47 +49.08% | -4.34 +123.71% | -1.94 -76.79% | -8.36 -268.21% | |
Diluted EPS and Net Income | -6.47 +49.08% | -4.34 +123.71% | -1.94 -76.79% | -8.36 -277.87% | |
Basic Weighted Average Shares | 89.9M +6.60% | 84.4M +6.49% | 79.2M +1.90% | 77.7M +2.37% | |
Diluted Weighted Average Shares | 89.9M +6.60% | 84.4M +6.49% | 79.2M +1.90% | 77.7M -3.29% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 347.6M +16.53% | 298.3M -23.42% | 389.5M +83.82% | 211.9M -77.04% | |
Short-Term Investments | 1.6B +1.41% | 1.6B +23.11% | 1.3B -18.66% | 1.6B +10.12% | |
Cash and Cash Equivalents and Short-Term Investments | 2.0B +3.78% | 1.9B +12.41% | 1.7B -6.70% | 1.8B -23.70% | |
Total Current Assets | 2.0B +2.51% | 1.9B +1.52% | 1.9B +2.97% | 1.9B -23.35% | |
Accumulated Depreciation | 91.1M +25.99% | 72.3M +35.26% | 53.4M +57.94% | 33.8M -10.51% | |
Property and Plant and Equipment and Net | 115.9M -13.60% | 134.1M -11.75% | 151.9M -7.14% | 163.6M +18.94% | |
Total Long-Term Assets | 24.4M +53.95% | 15.8M +701.47% | 2.0M -57.44% | 4.6M -12.30% | |
Total Assets | 2.3B +1.04% | 2.2B +0.56% | 2.2B -0.60% | 2.2B -18.49% | |
Income Taxes Payable | 1.1M +146.78% | 451,000 +2.97% | 438,000 +224.44% | 135,000 -81.35% | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 149.1M +69.88% | 87.8M -19.31% | 108.8M -10.17% | 121.1M +1.02% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 6.1M +78.34% | 3.4M +259.50% | 958,000 -83.95% | 6.0M -18.67% | |
Total Liabilities | 343.4M +10.80% | 310.0M -10.62% | 346.8M -5.66% | 367.6M +4.30% | |
Retained Earnings | -1.9B +42.58% | -1.4B +36.64% | -999.7M +18.16% | -846.1M +331.87% | |
Total Stockholders Equity | 1.9B -0.53% | 1.9B +2.62% | 1.9B +0.39% | 1.9B -21.84% | |
Total Shares Outstanding | 95.9M +11.84% | 85.7M +7.12% | 80.0M +1.95% | 78.5M +1.98% | |
Cash Flow | |||||
Cash from Operating Activities | -345.0M +141.65% | -142.8M -45.17% | -260.4M -47.48% | -495.7M -191.98% | |
Capital Expenditures | 914,000 -51.92% | 1.9M -79.93% | 9.5M -74.53% | 37.2M -54.49% | |
Cash from Investing Activities | -31.8M -88.66% | -280.5M -174.87% | 374.6M +244.84% | -258.7M -75.02% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 426.0M +28.33% | 332.0M +429.78% | 62.7M +62.38% | 38.6M -84.62% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | -1,250.38% +1,985.70% | -59.95% -99.89% | -56,190.40% -137,739.26% | |
Return on Assets | -25.81% +57.54% | -16.38% +138.48% | -6.87% -73.62% | -26.03% -257.85% | |
Return on Equity | -30.18% +57.19% | -19.20% +134.89% | -8.17% -73.13% | -30.42% -263.65% | |
Revenue Growth | -100.00% +11.18% | -89.95% -100.29% | 30,885.48% +31,025.96% | -99.87% -100.08% | |
Current Ratio | 13.32 -39.66% | 22.07 +25.82% | 17.54 +14.63% | 15.30 -24.12% | |
Cash Ratio | 2.33 -31.40% | 3.40 -5.09% | 3.58 +104.62% | 1.75 -77.28% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow